News

Prasad’s FDA exit may accelerate cell and gene therapy approvals
Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...
BioPharma Dive1h
Vinay Prasad’s ouster leaves biotech guessing at FDA direction
The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...
Stock market today: S&P 500 snaps 6-day record streak, stocks fall as earnings flood in, Fed decision looms
US stocks closed in the red Tuesday as investors digested a wave of corporate earnings and economic data, while bracing for ...
XBI: Surprise Exit Of A Tough Regulator At The FDA
The SPDR® S&P Biotech ETF rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a ...
US stock market futures edge higher today as Wall Street stays in ‘wait and see’ mode ahead of Fed decision
US stock futures rise before Fed as Wall Street holds its breath for a pivotal decision on interest rates and key earnings reports from tech giants like Microsoft and Meta. Markets are slightly up on ...